Table 1. Marmoset demographics and summary of results by experimental group.
| Experimental group | Marmoset | Sex/Age at study start (months) | Time to clinical symptoms (days) | Time between viral inoculation and sacrifice (months) | CNS samples positive for HHV-6 DNA/total surveyed | CNS region(s) positive for HHV-6 DNA |
| HHV-6A intravenous | M01* | F/173 | 49 | 14 | 0/9 | |
| M02* | F/45 | 29 | 12 | 0/10 | ||
| M03* | M/109 | 64 | 14 | 0/10 | ||
| M04* | M/28 | 27 | 14 | 1/9 | • Occipital cortex/cerebellum | |
| HHV-6B intravenous | M05* | M/99 | – | 8.5 | 1/10 | • Occipital cortex/cerebellum/brain stem |
| M06 | M/147 | – | ||||
| M07* | F/47 | – | 9 | 4/10 | • Occipital cortex/cerebellum | |
| • Prefrontal cortex | ||||||
| • Basal ganglia | ||||||
| • Cervical/thoracic spinal cord | ||||||
| M08* | F/42 | – | 16 | 0/8 | ||
| Vehicle Control intravenous | M09 | F/29 | – | |||
| M10 | F/29 | – | ||||
| M11 | F/20 | – | ||||
| HHV-6A intranasal | M12* | M/55 | – | 6.5 | 0/11 | |
| M13 | F/66 | – | ||||
| M14 | F/53 | – | ||||
| M15 | M/47 | – | ||||
| Total: 6/77 (8%) | ||||||